Sinotherapeutics Inc. A - Asset Resilience Ratio
Sinotherapeutics Inc. A (688247) has an Asset Resilience Ratio of 43.56% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Sinotherapeutics Inc. A's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Sinotherapeutics Inc. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 688247 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Sinotherapeutics Inc. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Sinotherapeutics Inc. A total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥633.46 Million | 43.56% |
| Total Liquid Assets | CN¥633.46 Million | 43.56% |
Asset Resilience Insights
- Very High Liquidity: Sinotherapeutics Inc. A maintains exceptional liquid asset reserves at 43.56% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sinotherapeutics Inc. A Industry Peers by Asset Resilience Ratio
Compare Sinotherapeutics Inc. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Sinotherapeutics Inc. A (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Sinotherapeutics Inc. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 23.60% | CN¥339.34 Million ≈ $49.66 Million |
CN¥1.44 Billion ≈ $210.44 Million |
-11.34pp |
| 2024-12-31 | 34.94% | CN¥507.74 Million ≈ $74.30 Million |
CN¥1.45 Billion ≈ $212.66 Million |
-- |
About Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more